Clinical trialNCT00273390CompletedInterventional

A Clinical Trial of Infliximab for Uveitis

SponsorOregon Health and Science UniversityEnrollment32Uveitis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This project is designed to test the hypothesis that inhibition of binding between tumor necrosis factor alpha (TNF-alpha) and its receptors using Remicade (infliximab, chimeric mouse/human IgG1K monoclonal antibody directed against human TNF-alpha, Centocor, Malvern,PA) is clinically useful for patients with uveitis that is refractory to other forms of systemic immunosuppressive therapy.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Eric B Suhler, MD
Oregon Health and Science University
Study DirectorKOL profile →
clinicaltrials.gov ↗
James T Rosenbaum, MD
Oregon Health and Science University
Principal Investigator
clinicaltrials.gov ↗
Justine Smith, MBBS, Phd
Oregon Health and Science University
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Remicade

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Aug 2001
Primary completion: 31 Dec 2006
Completion: 31 Dec 2006
Last update posted: 4 Jul 2011
Registered enrollment: 32
Registry id: NCT00273390

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.